IDDF2024-ABS-0269 Results from an integrated analysis at week 96: continued treatment of early virologic non-responder or partial responders with bulevirtide monotherapy for chronic hepatitis d leads to improvement in virologic and biochemical respon
<h3>Background</h3> Bulevirtide (BLV) is approved in Europe for the treatment of chronic hepatitis D (CHD). Optimal BLV monotherapy duration for CHD is unknown). This analysis evaluated BLV monotherapy in pts without VR after 24W. <h3>Methods</h3> Results from pts who completed BLV monotherapy for 96W in the Phase 3 (MYR301) and Phase 2 (MYR204) studies were included. NR and PR were defined as HDV RNA declines of <1 log10 IU/mL and ≥1 but <2 log10 IU/mL, respectively. Rates of biochemical response (alanine aminotransferase [ALT] within normal limits [WNL]) were compared. <h3>Results</h3> At W24, 65% pts had VR (58% with ALT WNL), 24% had PR (56% with ALT WNL), and 11% had NR (13% with ALT WNL) (IDDF2024-ABS-0269 Table 1). <h3>Conclusions</h3> Of 49 pts without VR at W24, the majority with PR and nearly half with NR were able to achieve VR at W96. ALT improved in all viral-response groups, including those with NR.
Authors
- Markus Cornberg (ORCID: https://orcid.org/0000-0002-9141-8001)
- Anu Osinusi
- Dmitry Manuilov
- Tarik Asselah (ORCID: https://orcid.org/0000-0002-0024-0595)
- Mark Bourliere
- Pavel Bogomolov (ORCID: https://orcid.org/0000-0003-2346-1216)
- Renée-Claude Mercier (ORCID: https://orcid.org/0000-0001-5983-6732)
- Tatyana Stepanova (ORCID: https://orcid.org/0000-0001-7177-2575)
- Soo Aleman (ORCID: https://orcid.org/0000-0003-0461-4870)
- Stefan Zeuzem (ORCID: https://orcid.org/0000-0002-0845-6833)
- Dominique Roulot (ORCID: https://orcid.org/0000-0003-0926-3563)
- John F. Flaherty (ORCID: https://orcid.org/0000-0002-4050-8234)
- Fabien Zoulim (ORCID: https://orcid.org/0000-0002-2245-0083)
- H. Fontaine
- Carrie Frenette
- Heiner H. Wedemeyer (ORCID: https://orcid.org/0000-0003-2906-0480)
- Grace M. Chee (ORCID: https://orcid.org/0009-0007-2616-3544)
- Maurizia Rossana Brunetto (ORCID: https://orcid.org/0000-0001-8364-9152)
- George Sebastian Gherlan (ORCID: https://orcid.org/0000-0003-3994-5020)
- Audrey Lau
- Ben L. Da (ORCID: https://orcid.org/0000-0002-7750-240X)
- Qi An (ORCID: https://orcid.org/0000-0002-6444-7157)
- Pietro Lampertico (ORCID: https://orcid.org/0000-0002-1026-7476)
- Jacques Yu
- Adrian Streinu-Cercel
Institutions
- Goethe University Frankfurt (DE)
- Karolinska University Hospital (SE)
- Carol Davila University of Medicine and Pharmacy (RO)
- University of Milan (IT)
- Université Paris Cité (FR)
- Hôpital Beaujon (FR)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Karolinska Institutet (SE)
- Medizinische Hochschule Hannover (DE)
- Sorbonne Université (FR)
- Hôpital de la Croix-Rousse (FR)
- Université Sorbonne Paris Nord (FR)
- Institutul National Victor Babes (RO)
- Hôpital Saint Joseph (FR)
- Moscow Institute of Modern Business (RU)
- University Hospital Frankfurt (DE)
- Gilead Sciences (United States) (US)
- Azienda Ospedaliera Universitaria Pisana (IT)
Publication Details
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/gutjnl-2024-iddf.194
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00